Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

Literature DB >> 21625932

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

Steffen Hess¹, Toni Hospach, Robert Nossal, Günther Dannecker, Klaus Magdorf, Frank Uhlemann.

Abstract

Life-threatening disseminated tuberculosis developed in a 17-year-old girl who was treated with the TNF-α blocker adalimumab for refractory SAPHO syndrome. The patient presented to the emergency department with dyspnea and somnolence and within 2 h developed the clinical picture of a septic shock. In addition to this unusual presentation, she showed a complicated course with increasing cerebral granuloma formation in spite of adequate antimycobacterial treatment. Immune reconstitution after discontinuation of TNF blockade may contribute to this "paradoxical reaction." Possible implications for screening, diagnosis, and treatment of tuberculosis in children and adolescents receiving anti-TNF treatment are discussed.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21625932 DOI： 10.1007/s00431-011-1501-y

Source DB: PubMed Journal: Eur J Pediatr ISSN： 0340-6199 Impact factor: 3.183

34 in total

1. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.

Authors: Carolina Garcia Vidal; Serena Rodríguez Fernández; Javier Martínez Lacasa; Miquel Salavert; Rafael Vidal; Monica Rodríguez Carballeira; Javier Garau
Journal: Clin Infect Dis Date: 2005-02-04 Impact factor: 9.079

2. Granulomatous infections due to tumor necrosis factor blockade: correction.

Authors: Robert S Wallis; Michael Broder; John Wong; David Beenhouwer
Journal: Clin Infect Dis Date: 2004-10-15 Impact factor: 9.079

3. Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays.

Authors: A L Endean; S M Barry; S A Young-Min
Journal: Rheumatology (Oxford) Date: 2008-12-24 Impact factor: 7.580

4. Antirheumatic drugs and the risk of tuberculosis.

Authors: Paul Brassard; Abbas Kezouh; Samy Suissa
Journal: Clin Infect Dis Date: 2006-08-10 Impact factor: 9.079

Review 5. Management of central nervous system tuberculosis in children: light and shade.

Authors: D Buonsenso; D Serranti; P Valentini
Journal: Eur Rev Med Pharmacol Sci Date: 2010-10 Impact factor: 3.507

6. Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors: R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal: Clin Infect Dis Date: 2004-04-15 Impact factor: 9.079

Review 7. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Authors: Susan Shenoi; Carol A Wallace
Journal: Paediatr Drugs Date: 2010-12-01 Impact factor: 3.022

8. Adalimumab treatment of life-threatening tuberculosis.

Authors: Robert S Wallis; Cloete van Vuuren; Samantha Potgieter
Journal: Clin Infect Dis Date: 2009-05-15 Impact factor: 9.079

9. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test.

Authors: B Kampmann; E Whittaker; A Williams; S Walters; A Gordon; N Martinez-Alier; B Williams; A M Crook; A-M Hutton; S T Anderson
Journal: Eur Respir J Date: 2009-02-05 Impact factor: 16.671

10. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study.

Authors: Johan F Schoeman; Priscilla Springer; Anita Janse van Rensburg; Sonja Swanevelder; Willem A Hanekom; Patrick A J Haslett; Gilla Kaplan
Journal: J Child Neurol Date: 2004-04 Impact factor: 1.987

11 in total

1. Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population.

Authors: Basak Yildiz Atikan; Cengiz Cavusoglu; Merve Dortkardesler; Betul Sozeri
Journal: Clin Rheumatol Date: 2014-12-18 Impact factor: 2.980

Review 2. The Interplay Between Systemic Inflammation, Oxidative Stress, and Tissue Remodeling in Tuberculosis.

Authors: Eduardo P Amaral; Caian L Vinhaes; Deivide Oliveira-de-Souza; Betania Nogueira; Kevan M Akrami; Bruno B Andrade
Journal: Antioxid Redox Signal Date: 2020-06-19 Impact factor: 8.401

Review 3. Immune reconstitution inflammatory syndrome associated with biologic therapy.

Authors: Malika Gupta; Kashif Jafri; Rebecca Sharim; Susanna Silverman; Sayantani B Sindher; Anupama Shahane; Mildred Kwan
Journal: Curr Allergy Asthma Rep Date: 2015-02 Impact factor: 4.919

Review 4. Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.

Authors: Katherine Anne B Marzan
Journal: Adolesc Health Med Ther Date: 2012-06-20

5. Prolonged paradoxical reaction to anti-tuberculous treatment after discontinuation of TNF-alpha- blocker therapy with adalimumab. Rare clinical documentation.

Authors: Roger Fei Falkenstern-Ge; Kim Husemann; Martin Kohlhäufl
Journal: Open Med (Wars) Date: 2014-10-08

6. HOW TO TREAT PATIENTS AFTER SERIOUS ADVERSE EFFECTS CAUSED BY TNF INHIBITORS?

Authors: Saša Sršen; Eugenija Marušić; Vitomir Metličić; Luka Stričević; Marijan Frković; Marija Jelušić
Journal: Acta Clin Croat Date: 2020-03 Impact factor: 0.780

Review 7. New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.

Authors: Wei Cheng; Fen Li; Jing Tian; Xi Xie; Jin-Wei Chen; Xiao-Fei Peng; Qi Tang; Yan Ge
Journal: J Inflamm Res Date: 2022-04-13

Review 8. Clinical review: tuberculosis on the intensive care unit.

Authors: Guy Hagan; Nazim Nathani
Journal: Crit Care Date: 2013-09-27 Impact factor: 9.097

9. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.

Authors: Joan Calzada-Hernández; Jordi Anton-López; Rosa Bou-Torrent; Estíbaliz Iglesias-Jiménez; Sílvia Ricart-Campos; Javier Martín de Carpi; Vicenç Torrente-Segarra; Judith Sánchez-Manubens; Clara Giménez-Roca; Librada Rozas-Quesada; Maria Teresa Juncosa-Morros; Clàudia Fortuny; Antoni Noguera-Julian
Journal: Pediatr Rheumatol Online J Date: 2015-12-03 Impact factor: 3.054

Review 10. Use of steroids to treat anti-tumor necrosis factor α induced tuberculosis-associated immune reconstitution inflammatory syndrome: Case report and literature review.

Authors: Daijiro Nabeya; Takeshi Kinjo; Kazutaka Yamaniha; Shoshin Yamazato; Reo Tome; Kazuya Miyagi; Hideta Nakamura; Tetsu Kinjo; Shusaku Haranaga; Futoshi Higa; Jiro Fujita
Journal: Medicine (Baltimore) Date: 2020-10-23 Impact factor: 1.817